D-Cycloserine Phase 4 Hereditary Spastic Paraplegia Trial
Summary
NIH registered a Phase 4 clinical trial (NCT07542548) investigating D-cycloserine for serine palmitoyltransferase inhibition to mitigate neurological decline associated with SPTSSA-related Complex Hereditary Spastic Paraplegia. The single-arm trial lists 25 participants with D-cycloserine as the sole intervention. This is an informational registration entry on ClinicalTrials.gov, not a regulatory approval or safety action.
What changed
A new clinical trial registration for NCT07542548 was added to ClinicalTrials.gov. The trial will study D-cycloserine, a serine palmitoyltransferase inhibitor, in approximately 25 participants with hereditary spastic paraplegia linked to SPTSSA mutations. The estimated start date is April 21, 2026.
For pharmaceutical companies, clinical investigators, and healthcare providers involved in rare neurological disorders, this registration signals an active Phase 4 investigation into an orphan neurological indication. D-cycloserine's prior use in other neurological conditions may inform understanding of the drug's safety profile in this population.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
D-Cycloserine for Serine Palmitoyltransferase Inhibition
Phase 4 NCT07542548 Kind: PHASE4 Apr 21, 2026
Abstract
The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia
Conditions: Hereditary Spastic Paraplegia
Interventions: D-cycloserine
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.